Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Meena Subramanyam"'
Autor:
Joleen T. White, Scott D. Newsome, Bernd C. Kieseier, Robert A. Bermel, Yue Cui, Ali Seddighzadeh, Serena Hung, Mary Crossman, Meena Subramanyam
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Background: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation i
Externí odkaz:
https://doaj.org/article/218894cfb2cd433b9f87df69b742ddd1
Publikováno v:
Current Opinion in Toxicology. 4:35-42
Predicting the potential of biopharmaceuticals to induce adverse immunologic events has become increasingly complex due to the diversity of treatment modalities and their structural complexity. Furthermore, unintentional or unexpected effects on immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88c345d126c321b5f09574cf2c6f7503
https://doi.org/10.1016/j.cotox.2017.03.004
https://doi.org/10.1016/j.cotox.2017.03.004
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Autor:
Tatiana Plavina, Kumar Kandadi Muralidharan, Daniel Mikol, Meena Subramanyam, Sreeja Gopal, Geoffrey Kuesters, Ivan Nestorov
Publikováno v:
The Journal of Clinical Pharmacology. 57:1017-1030
Natalizumab (humanized immunoglobulin G4 antibody targeting alpha-4 integrins) is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS) that has been in clinical use since 2006. However, natalizumab pharmacokinetic (PK) cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ebc40abe1d445c88c2c45f80123e38
https://doi.org/10.1002/jcph.894
https://doi.org/10.1002/jcph.894
Autor:
Dan Mikol, Ivan Nestorov, Diogo Amarante, Kumar Kandadi Muralidharan, Pei-Ran Ho, Jacob Elkins, Deb Steiner, Meena Subramanyam
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 44:263-275
Natalizumab, a human immunoglobulin monoclonal antibody that targets α4β1/α4β7 integrin, is an effective therapy approved for the treatment of multiple sclerosis (MS). The objective of this analysis was to develop a population exposure–response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f5bad6ce0fa1a854509e0c9b49d2f98
https://doi.org/10.1007/s10928-017-9514-4
https://doi.org/10.1007/s10928-017-9514-4
Autor:
Akiko Ishii-Watabe, Albert Torri, Rong Zeng, Daniel Kramer, Steven P. Piccoli, David J. Uhlinger, Stephanie Fraser, Patricia Siguenza, Afshin Safavi, John Smeraglia, Apollon Papadimitriou, Yan G. Ni, Susan M. Richards, Kyra J. Cowan, Alessandra Vitaliti, Lakshmi Amaravadi, Boris Gorovits, Gustavo Mendes Lima Santos, John Kadavil, Sam Haidar, Jan Welink, Yongchang Qiu, João Pedras-Vasconcelos, Chan C. Whiting, Li Xue, Christina Satterwhite, John Kamerud, Swati Gupta, Natasha Savoie, Herbert Birnboeck, Yoshiro Saito, Paul Rhyne, Fabrizio Galliccia, Laurent Cocea, Stephanie Croft, Bonnie Wu, Theingi M. Thway, Virginia Litwin, Corinna Krinos-Fiorotti, Darshana Jani, Charles S Hottenstein, Vinita Gupta, Roland F Staack, Fabio Garofolo, Eginhard Schick, Kara Scheibner, Meena Subramanyam, John Allinson, Renuka Pillutla, Robert Nelson, Flora Berisha, Martin Ullmann, Giane Sumner
Publikováno v:
Bioanalysis. 8:2475-2496
The 2016 10th Workshop on Recent Issues in Bioanalysis (10th WRIB) took place in Orlando, Florida with participation of close to 700 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a67282718390ee4d7f9eb9599bdcf67
https://doi.org/10.4155/bio-2016-4989
https://doi.org/10.4155/bio-2016-4989
Autor:
Jaya Goyal, Meena Subramanyam
Publikováno v:
Drug Discovery Today: Technologies. :3-10
The refinement of disease taxonomy utilizing molecular phenotypes has led to significant improvements in the precision of disease diagnosis and customization of treatment options. This has also spurred efforts to identify novel biomarkers to understa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975fa1adf3a15e2ccb8e1fd01ef9a843
https://doi.org/10.1016/j.ddtec.2016.10.001
https://doi.org/10.1016/j.ddtec.2016.10.001
Publikováno v:
European Journal of Neurology. 21:299-304
Background and purpose Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of JC virus (JCV) infection due to combined host and viral factors. Anti-JCV antibodies provide a means to assess JCV exposure and stratify PML risk. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9431d6a3a7f859bffc005a142b288e85
https://doi.org/10.1111/ene.12304
https://doi.org/10.1111/ene.12304
Autor:
Melissa Berman, Brian Schlain, Tatiana Plavina, Peter T. Lee, Dipeshkumar Jaiswal, Albert Castro, Suzanne Rivas, Meena Subramanyam
Publikováno v:
Journal of Clinical Virology. 57:141-146
Background JC virus (JCV) infection is a prerequisite for development of progressive multifocal leukoencephalopathy (PML). The development and validation of a two-step enzyme-linked immunosorbent assay (ELISA) that detects JCV antibodies in human ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d2114be5c313bfb1d77c19d766646c5
https://doi.org/10.1016/j.jcv.2013.02.002
https://doi.org/10.1016/j.jcv.2013.02.002
Autor:
Anne Kathrin Trampe, Poul Erik Hyldgaard Jensen, Lucia Moiola, David Brassat, Jan Hillert, Kjell-Morten Myhr, Annette Bang Oturai, Anat Achiron, Tatiana Plavina, James Potts, Heinz Wiendl, Thomas Berger, Dorothea Buck, Mefkure Eraksoy, Deniz Uren, Giancarlo Comi, Tomas Olsson, Hussein Dib, Sven Schippling, Aksel Siva, Harald Hegen, Andrew T. Chan, Lars Alfredsson, Bernhard Hemmer, Meena Subramanyam, Thomas Weber, Per Soelberg Sørensen, D Paes
Publikováno v:
Multiple Sclerosis Journal. 19:1533-1538
JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c65f08a3067e4ad420b212d47c8f31
https://doi.org/10.1177/1352458513477925
https://doi.org/10.1177/1352458513477925
Autor:
Jan Willem van der Laan, Ian Kimber, Dean J. Naisbitt, Meena Subramanyam, Swaminathan Sethu, Marque Todd, Karthik Govindappa, Jennifer Sims, David Jones, Richard J. Weaver, Stephen T. Holgate, B. Kevin Park, Neil French, Lolke de Haan, Jean G. Sathish, Christopher E.M. Griffiths, James D. Green, Marie Christine Bielsky, Gabriele Reichmann, Jonathan G. Moggs, Munir Pirmohamed
Publikováno v:
Nature Reviews. Drug Discovery
Key Points Immunomodulatory biologics are a class of biotechnology-derived therapeutic products that are designed to engage immune-relevant targets and are indicated in the treatment and management of a range of diseases, including immune-mediated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e40b3b36710a96b017a86f60343fd9c
http://europepmc.org/articles/PMC7097261
http://europepmc.org/articles/PMC7097261